Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) [Phase 3]

View source ↗

Summary

The Phase 3 KEYNOTE-522 trial evaluating pembrolizumab with chemotherapy as neoadjuvant therapy and pembrolizumab as adjuvant therapy in triple-negative breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Triple Negative Breast Neoplasms | Phase 3 | Status: COMPLETED